Loubani Lamees, Bartlett Jenna W, Mothner Brent, Asaithambi Rathi, Lee Surin
Department of Pharmacy (LL, SL, JWB), Texas Children's Hospital, Houston, TX.
Department of Pediatrics (BM, RA), Division of Pediatric Hospital Medicine, Baylor College of Medicine, Houston, TX.
J Pediatr Pharmacol Ther. 2024 Dec;29(6):630-635. doi: 10.5863/1551-6776-29.6.630. Epub 2024 Dec 9.
The primary aim of this study was to determine continuation rates of stress ulcer prophylaxis (SUP) upon transfer from a pediatric intensive care unit (PICU) to a general medicine unit and upon hospital discharge. The secondary aim was to identify patient characteristics or concomitant medications that were associated with continuation of SUP at transfer from the PICU.
This retrospective chart review included patients who were initiated on acid suppression for SUP in the PICU between June 2021 and May 2022 and subsequently transferred to a general medicine unit prior to discharge. Patients were excluded if they were receiving acid suppressant therapy prior to admission or were started on acid suppressants for an indication other than SUP.
Two hundred three patients (median age, 3.3 years) were included. The rates of SUP continuation at the time of transfer from the PICU to a general medicine unit and at hospital discharge were 61.6% and 9.9%, respectively. Patients continued on SUP at the time of transfer from the PICU were more likely to be prescribed concomitant corticosteroids (p < 0.01), anticoagulants or antiplatelet medications (p < 0.01).
The continuation of SUP from the PICU to the general medicine unit is common at our institution and calls into question the appropriateness of this practice. Future research is warranted to investigate the appropriateness of the continuation of SUP at transitions of care. Additionally, implementation of institutional protocols standardizing review of SUP may help reduce unnecessary prescribing of acid suppressants in general medicine units and at discharge.
本研究的主要目的是确定从儿科重症监护病房(PICU)转至普通内科病房以及出院时应激性溃疡预防(SUP)的持续率。次要目的是确定与从PICU转出时SUP持续使用相关的患者特征或伴随用药情况。
这项回顾性病历审查纳入了2021年6月至2022年5月期间在PICU开始接受抑酸治疗以进行SUP且随后在出院前转至普通内科病房的患者。如果患者在入院前接受抑酸治疗或因SUP以外的适应症开始使用抑酸剂,则将其排除。
共纳入203例患者(中位年龄3.3岁)。从PICU转至普通内科病房时以及出院时SUP的持续率分别为61.6%和9.9%。从PICU转出时继续接受SUP治疗的患者更有可能同时使用皮质类固醇(p<0.01)、抗凝剂或抗血小板药物(p<0.01)。
在我们机构中,从PICU到普通内科病房持续进行SUP很常见,这一做法的合理性值得质疑。有必要进行进一步研究以调查在护理过渡期间继续进行SUP的合理性。此外,实施规范SUP审查的机构规程可能有助于减少普通内科病房和出院时酸抑制剂的不必要处方。